Phase II clinical trial - Phases précoces tumeurs solides

Phases précoces tumeurs solides
Essai clinique fermé
Public cible
Phase II basket trial evaluating the efficacy of a combination of;pembrolizumab and vorinostat in patients with recurrent and/or;metastatic squamous cell carcinoma
Description de l'essai
Efficacy of immunotherapy in combination with a drug in patients with;advanced mucosal cancer of different locations that has progress.Patients will be treated until disease progression (or for up to 35 cycles for pembrolizumab) or;unacceptable toxicity or patient decision.;Continuation of pembrolizumab beyond 35 cycles may be allowed under certain conditions and;must be agreed with the sponsor before continuing the treatment.